Eliquis and Ambien drug interactions - a phase IV clinical study of FDA data
Drug interactions are reported among people who take Eliquis and Ambien. Common interactions include oropharyngeal pain among females and pneumonia among males.
The phase IV clinical study analyzes what interactions people who take Eliquis and Ambien have. It is created by eHealthMe based on reports of 610 people who take Eliquis and Ambien from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
610 people who take Eliquis and Ambien together, and have interactions are studied.
What is Eliquis?
Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 119,696 Eliquis users for its effectiveness, alternative drugs and more.
What is Ambien?
Ambien has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 87,507 Ambien users for its effectiveness, alternative drugs and more.
Number of Eliquis and Ambien reports submitted per year:
Eliquis and Ambien drug interactions by gender *:
Eliquis and Ambien drug interactions by age *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Eliquis and Ambien?Personalize this study to your gender and age
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Hsu FG, Sheu MJ, Lin CL, Hsieh YW, Lai SW, "Use of Zolpidem and Risk of Acute Pyelonephritis in Women: A Population‐Based Case‐Control Study in Taiwan", The Journal of Clinical Pharmacology, 2017 Mar .
- Lin SC, Su YC, Huang YS, Lee CC, "Zolpidem increased cancer risk in patients with sleep disorder: A 3-year follow-up study", Journal of Medical Sciences, 2016 Mar .
- Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH, "Association between zolpidem and suicide: a nationwide population-based case-control study", InMayo Clinic Proceedings, 2016 Mar .
- Liao KF, Lin CL, Lai SW, Chen WC, "Zolpidem use associated with increased risk of pyogenic liver abscess: a case-control study in Taiwan", Medicine, 2015 Jan .
Alternative drugs to, pros and cons of the 2 drugs:
Common Eliquis and Ambien interactions:
Browse all drug interactions of Eliquis and Ambien:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Eliquis interactions:
Browse all interactions between Eliquis and drugs from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
Common Ambien interactions:
Browse all interactions between Ambien and drugs from A to Z:a b c d e f g h i j k l m n o p q r s t u v w x y z
How the study uses the data?
The study uses data from the FDA. It is based on apixaban and zolpidem tartrate (the active ingredients of Eliquis and Ambien, respectively), and Eliquis and Ambien (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.